Investigational drug · Phase 3
SKY-0515
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Huntington Disease, Huntingtons Disease, Huntington's Disease (HD).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "SKY-0515"
First trial start
2025
May 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SKY-0515", any sponsor or status.
Conditions studied
As listed on its trial records.
- Huntington Disease
- Huntingtons Disease
- Huntington's Disease (HD)
Approved drugs for the same conditions: Huntington's disease chorea · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "SKY-0515" as an intervention, largest first.
- An Extension of SKY-0515 in Participants With Huntington's DiseasePivotal-lookingEnrolling by invitation
Skyhawk Therapeutics, Inc.Industry
NCT07537075 · 500 participants (planned) · Start Apr 10, 2026 · Primary completion Dec 2029
Drug: SKY-0515 · For: Huntington's Disease (HD)
Sites: New Lambton Heights, Australia; Westmead, Australia; Herston, Australia · 10 sites in all
- Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's DiseasePivotal-lookingRecruiting
Skyhawk Therapeutics, Inc.Industry
NCT07378644 · 400 participants (planned) · Start Jan 6, 2026 · Primary completion Dec 2028
Drug: SKY-0515; SKY-0515 Placebo · For: Huntington Disease
Sites: Englewood, Colorado; Boston, Massachusetts; Charlestown, Massachusetts · 31 sites in all
- Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's DiseasePivotal-lookingActive, not recruiting
Skyhawk Therapeutics, Inc.Industry
NCT06873334 · 120 participants (planned) · Start May 27, 2025 · Primary completion May 2027
Drug: SKY-0515; SKY-0515 Placebo · For: Huntington Disease; Huntingtons Disease
Sites: New Lambton Heights, Australia; Westmead, Australia; Herston, Australia · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Huntington's disease clinical trials update: August 2026.
Farag M, Kinyomi O, Tabrizi SJ, et al. · J Huntingtons Dis 2026
- Huntington's disease clinical trials update: October 2025.
Farag M, Tabrizi SJ, Wild EJ · J Huntingtons Dis 2026
Also in development for Huntington Disease
- PridopidinePhase 32 trials
Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease
- ER2001Phase 21 trial
ExoRNA Bioscience · Huntington Disease
- MBF-015Phase 21 trial
Medibiofarma S.L. · Huntington Disease
- TominersenRO7234292, RG6042Phase 21 trial
Roche (Genentech) · Huntington Disease
- VO659Phase 21 trial
Vico Therapeutics B. V. · Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.